{"title":"非皮质类固醇抗炎药在SARs-CoV-2肺炎中的应用","authors":"P. Theerawit","doi":"10.54205/ccc.v29i.252686","DOIUrl":null,"url":null,"abstract":"The SARs-CoV-2 results in hyperinflammation among infected patients. This condition leads to serious organ injury, especially in the lungs. Therefore, the main treatment option, in addition to anti-viral agents, is the administration of corticosteroids. However, in many cases, inadequate response to corticosteroids has been observed—other anti-inflammatory agents, such as interleukin-6 inhibitor, kinase inhibitor, etc., play an essential role in reducing this severe complication.","PeriodicalId":76963,"journal":{"name":"AACN clinical issues in critical care nursing","volume":"115 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia\",\"authors\":\"P. Theerawit\",\"doi\":\"10.54205/ccc.v29i.252686\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The SARs-CoV-2 results in hyperinflammation among infected patients. This condition leads to serious organ injury, especially in the lungs. Therefore, the main treatment option, in addition to anti-viral agents, is the administration of corticosteroids. However, in many cases, inadequate response to corticosteroids has been observed—other anti-inflammatory agents, such as interleukin-6 inhibitor, kinase inhibitor, etc., play an essential role in reducing this severe complication.\",\"PeriodicalId\":76963,\"journal\":{\"name\":\"AACN clinical issues in critical care nursing\",\"volume\":\"115 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AACN clinical issues in critical care nursing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54205/ccc.v29i.252686\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AACN clinical issues in critical care nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54205/ccc.v29i.252686","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia
The SARs-CoV-2 results in hyperinflammation among infected patients. This condition leads to serious organ injury, especially in the lungs. Therefore, the main treatment option, in addition to anti-viral agents, is the administration of corticosteroids. However, in many cases, inadequate response to corticosteroids has been observed—other anti-inflammatory agents, such as interleukin-6 inhibitor, kinase inhibitor, etc., play an essential role in reducing this severe complication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
